H.C. Wainwright Raises Price Target for MoonLake Immunotherapeutics (MLTX) Following FDA Progress
H.C. Wainwright raised the price target for MoonLake Immunotherapeutics (NASDAQ:MLTX) to $45 from $40, maintaining a 'Buy' rating due to positive regulatory progress on sonelokimab. The company is preparing a biologics license application submission in late September 2026 and has strong cash reserves.
Tickers: $MLTX
Topics: Biotech Stock FDA Progress Pharmaceuticals